Oral pharmaceutical composition for treating diabetic

A composition and a technology for diabetes, applied in the field of medicine, can solve the problem that there is no literature report on the anti-diabetic activity of kava kava kava

Active Publication Date: 2018-04-24
王磊
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No literature has reported the antidiabetic activi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral pharmaceutical composition for treating diabetic
  • Oral pharmaceutical composition for treating diabetic
  • Oral pharmaceutical composition for treating diabetic

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Granules for treating diabetes and their preparation

[0027]

[0028] Preparation:

[0029] A: Take kavabirin B and pimophanserin tartrate through a 100-mesh sieve, and mix well.

[0030] B: Take lactose, microcrystalline cellulose, and cross-linked povidone through a 100-mesh sieve, and mix them evenly. Of which milk

[0031] The amount of sugar is 2.0 times the weight of kavabiodin B; the amount of microcrystalline cellulose is 1.2 times the weight of kavabiodin B; the amount of crospovidone is 0.12 times the weight of kavabiodin B

[0032] C: Mix the powders obtained in step A and step B uniformly.

[0033] D: Take povidone K30, add water and stir to make a liquid dispersion system. The dosage of povidone K30 is 0.17 times the weight of kavabiotin B; the dosage of water is 32.3 times the weight of povidone K30.

[0034] E: Add the liquid dispersion system obtained in step D to the powder obtained in step C, granulate and dry, and pass the dry granules through a 20-m...

Embodiment 2

[0036] Example 2 Granules for treating diabetes and their preparation

[0037]

[0038] Preparation:

[0039] A: Take kavabirin B and pimophanserin tartrate through a 100-mesh sieve, and mix well.

[0040] B: Take lactose, microcrystalline cellulose, and cross-linked povidone through a 100-mesh sieve, and mix them evenly. Of which milk

[0041] The amount of sugar is 2.0 times the weight of kavabiodin B; the amount of microcrystalline cellulose is 1.2 times the weight of kavabiodin B; the amount of crospovidone is 0.12 times the weight of kavabiodin B

[0042] C: Mix the powders obtained in step A and step B uniformly.

[0043] D: Take povidone K30, add water and stir to make a liquid dispersion system. The dosage of povidone K30 is 0.17 times the weight of kavabiotin B; the dosage of water is 32.3 times the weight of povidone K30.

[0044] E: Add the liquid dispersion system obtained in step D to the powder obtained in step C, granulate and dry, and pass the dry granules through a 20-m...

Embodiment 3

[0046] Example 3 Granules for treating diabetes and their preparation

[0047]

[0048] Preparation:

[0049] A: Take kavabirin B and pimophanserin tartrate through a 100-mesh sieve, and mix well.

[0050] B: Take lactose, microcrystalline cellulose, and cross-linked povidone through a 100-mesh sieve, and mix them evenly. Of which milk

[0051] The amount of sugar is 2.0 times the weight of kavabiodin B; the amount of microcrystalline cellulose is 1.2 times the weight of kavabiodin B; the amount of crospovidone is 0.12 times the weight of kavabiodin B

[0052] C: Mix the powders obtained in step A and step B uniformly.

[0053] D: Take povidone K30, add water and stir to make a liquid dispersion system. The dosage of povidone K30 is 0.17 times the weight of kavabiotin B; the dosage of water is 32.3 times the weight of povidone K30.

[0054] E: Add the liquid dispersion system obtained in step D to the powder obtained in step C, granulate and dry, and pass the dry granules through a 20-m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicine, and particularly relates to an oral pharmaceutical composition for treating diabetic. The oral pharmaceutical composition is prepared from, by weight, pharmaceutically acceptable excipients, 11-23 parts of kava piperine B and 5-10 parts of tartaric acid pimavanserin. The oral pharmaceutical composition is granules preferably. Animal experiments showthat a compound of kava piperine B and tartaric acid pimavanserin has good antidiabetic effect and safety.

Description

Technical field [0001] The invention belongs to the field of medicine, and specifically relates to an oral pharmaceutical composition for treating diabetes. Background technique [0002] Diabetes is a chronic and complex metabolic disease characterized by abnormal glucose metabolism and pathological increase in blood sugar. It is a type of disease caused by relative or absolute deficiency of insulin. At present, diabetes has become one of the three chronic non-communicable diseases threatening human health. There are more than 92.4 million people with diabetes in China between the ages of 20 and 79, accounting for about a quarter of the total number of patients in the world, and the prevalence is increasing and younger. For a long time to come, diabetes will still be one of the main diseases leading to an increase in the burden of health care. [0003] With the gradual deepening and expansion of basic research, in addition to traditional anti-diabetic drugs such as insulin, sulfo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/12A61K31/4468A61K9/16A61P3/10
CPCA61K9/1652A61K31/12A61K31/4468A61K2300/00
Inventor 王磊崔丽媛吕范凯
Owner 王磊
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap